Journal
VACCINE
Volume 36, Issue 19, Pages 2694-2704Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2018.03.040
Keywords
ASFV; Recombinants; Deletion mutants; LAVs; NH/P68; Armenia07/Arm07
Categories
Funding
- EU project ASFRISK, Evaluating and Controlling the Risk of African Swine Fever in the EU, (DG-Research, EC, 7FP) [KBBE211691]
- EU project ASFORCE, Targeted Research Effort on African Swine Fever (DG-Research, EC, 7FP Grant) [KBBE.2012.1.3-02, 311931]
- EU [UE-LR PPA/03]
Ask authors/readers for more resources
The risk of spread of African swine fever virus (ASFV) from Russia and Caucasian areas to several EU countries has recently emerged, making it imperative to improve our knowledge and defensive tools against this important pathogen. The ASFV genome encodes many genes which are not essential for virus replication but are known to control host immune evasion, such as NFxB and the NFAT regulator A238L, the apoptosis inhibitor A224L, the MHC-I antigen presenting modulator EP153R, and the A276R gene, involved in modulating type I IFN. These genes are hypothesized to be involved in virulence of the genotype I parental ASFV NH/P68. We here describe the generation of putative live attenuated vaccines (LAV) prototypes by constructing recombinant NH/P68 viruses lacking these specific genes and containing specific markers. (C) 2018 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
